The Role of the Pharmacist in a Patient's Care for Individuals Undergoing Anticoagulant Therapy: A Case Report

Overview

Journal Life (Basel)

Specialty Biology

Date 2024 Aug 29

PMID 39202728

Authors

Ana M Saez-Benito

Loreto Saez-Benito

Maria Salazar

Rosa Magallon

Nuria Berenguer

Affiliations

Soon will be listed here.

Abstract

Achieving clinical effectiveness with vitamin K antagonists (VKAs) requires a Time in Therapeutic Range (TTR) above 65%. TTR is influenced by genetics (CYP2C9, VKORC1, CYP4F2), treatment adherence, and knowledge. The SAMe-TT2R2 algorithm is used to assess VKA treatment suitability. In this case report, SAMe-TT2R2 and pharmacogenetic analysis were used to improve oral anticoagulant management in a patient with poor control of INR. An 84-year-old, obese male with atrial fibrillation, undergoing acenocoumarol therapy, had a suboptimal TTR. An assessment with the SAMe-TT2R2 algorithm indicated a favorable profile for VKA use. An educational intervention on vitamin K-rich foods was conducted, and his physician was informed about the interaction between omeprazole and acenocoumarol, recommending its replacement with pantoprazole. This intervention was accepted by the physician and, three months post-intervention, the patient's TTR improved to 100%. Poor adherence and limited knowledge contributed to treatment failures in patients with a good VKA profile. Pharmaceutical interventions significantly improved TTR management. Patients with favorable genetic and clinical profiles could achieve adequate control of their anticoagulant medication through these interventions. Predictive tools may help select patients who can effectively and safely use VKAs through pharmaceutical interventions.

References

Diken A, Yalcinkaya A, Hanedan M, Erol M, Ercen Diken O . Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis. Phlebology. 2017; 33(1):53-59. DOI: 10.1177/0268355516688358. View

Jurcut R, Militaru S, Geavlete O, Dragotoiu N, Sipos S, Rosulescu R . Predictive factors for obtaining a correct therapeutic range using antivitamin K anticoagulants: a tertiary center experience of patient adherence to anticoagulant therapy. Patient Prefer Adherence. 2015; 9:1271-8. PMC: 4571932. DOI: 10.2147/PPA.S87066. View

Lanas F, Castro C, Vallejos C, Bustos L, De La Puente C, Velasquez M . Latin American Clinical Epidemiology Network Series - Paper 2: Apixaban was cost-effective vs. acenocoumarol in patients with nonvalvular atrial fibrillation with moderate to severe risk of embolism in Chile. J Clin Epidemiol. 2016; 86:75-83. DOI: 10.1016/j.jclinepi.2016.05.018. View

Leal B, Torres H, Roco A, Roman R, Rojo M, Nieto E . [Effects of pharmaceutical counseling on the effectiveness of anticoagulation in patients with atrial fibrillation]. Rev Med Chil. 2021; 149(5):724-732. DOI: 10.4067/s0034-98872021000500724. View

Apostolakis S, Sullivan R, Olshansky B, Lip G . Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest. 2013; 144(5):1555-1563. DOI: 10.1378/chest.13-0054. View

Tong H, Davila-Fajardo C, Borobia A, Martinez-Gonzalez L, Lubomirov R, Perea Leon L . A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population. PLoS One. 2016; 11(3):e0150456. PMC: 4792430. DOI: 10.1371/journal.pone.0150456. View

Agewall S, Cattaneo M, Collet J, Andreotti F, Lip G, Verheugt F . Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013; 34(23):1708-13, 1713a-1713b. DOI: 10.1093/eurheartj/eht042. View

Zuchinali P, Souza G, de Assis M, Rabelo E, Rohde L . Dietary vitamin K intake and stability of anticoagulation with coumarins: evidence derived from a clinical trial. Nutr Hosp. 2013; 27(6):1987-92. DOI: 10.3305/nh.2012.27.6.6068. View

Pinson G, Beall J, Kyle J . A review of warfarin dosing with concurrent acetaminophen therapy. J Pharm Pract. 2013; 26(5):518-21. DOI: 10.1177/0897190013488802. View

10.

Sanchez-Garrido Escudero R, Molina Casado M, Rodriguez Idigoras M, Martinez Gonzalez J, Escolar Castellon J . [Pharmacological interactions in patients treated with oral anticoagulants in a rural health area]. Aten Primaria. 2006; 38(8):427-32. PMC: 7669082. DOI: 10.1157/13094796. View

11.

Lozano R . Drug-drug interactions between acenocoumarol and proton pump inhibitors in hospitalized patients: Overanticoagulation associated with intravenous omeprazole. Int J Clin Pharmacol Ther. 2021; 59(10):671-673. DOI: 10.5414/CP203997. View

12.

Morisky D, Green L, Levine D . Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986; 24(1):67-74. DOI: 10.1097/00005650-198601000-00007. View

13.

Vasquez Ortiz L, Diaz Seijas D, Gordillo Campos N, Aguilar Alban A . [Knowledge about warfarin treatment in patients with atrial fibrillation or mechanical prosthetic valves]. Arch Peru Cardiol Cir Cardiovasc. 2023; 3(4):188-195. PMC: 10284579. DOI: 10.47487/apcyccv.v3i4.256. View

14.

Elkhazraji A, Bouaiti E, Boulahyaoui H, Nahmtchougli C, Zahid H, Bensaid M . Effect of CYP2C9, VKORC1, CYP4F2, and GGCX gene variants and patient characteristics on acenocoumarol maintenance dose: Proposal for a dosing algorithm for Moroccan patients. Drug Discov Ther. 2018; 12(2):68-76. DOI: 10.5582/ddt.2017.01063. View

15.

Pernod G, Labarere J, Yver J, Satger B, Allenet B, Berremili T . EDUC'AVK: reduction of oral anticoagulant-related adverse events after patient education: a prospective multicenter open randomized study. J Gen Intern Med. 2008; 23(9):1441-6. PMC: 2518037. DOI: 10.1007/s11606-008-0690-1. View

16.

Falamic S, Lucijanic M, Hadziabdic M, Marusic S, Vrca V . Pharmacist's interventions improve time in therapeutic range of elderly rural patients on warfarin therapy: a randomized trial. Int J Clin Pharm. 2018; 40(5):1078-1085. DOI: 10.1007/s11096-018-0691-z. View

17.

You J . Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis. J Gen Intern Med. 2013; 29(3):438-46. PMC: 3930767. DOI: 10.1007/s11606-013-2639-2. View

18.

Wallentin L, Yusuf S, Ezekowitz M, Alings M, Flather M, Franzosi M . Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010; 376(9745):975-83. DOI: 10.1016/S0140-6736(10)61194-4. View

19.

McInnes G, Lawson D, Jick H . Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis. 1981; 40(3):245-9. PMC: 1000756. DOI: 10.1136/ard.40.3.245. View

20.

Lakshmi R, James E, Kirthivasan R . Study on Impact of Clinical Pharmacist's Interventions in the Optimal Use of Oral Anticoagulants in Stroke Patients. Indian J Pharm Sci. 2013; 75(1):53-9. PMC: 3719150. DOI: 10.4103/0250-474X.113550. View